These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34152427)

  • 1. Reduced bendamustine for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Kurokawa M
    Ann Hematol; 2022 Mar; 101(3):713-715. PubMed ID: 34152427
    [No Abstract]   [Full Text] [Related]  

  • 2. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
    Alnuaimi K; Lavolé J; Lascoux-Combes C; Roque Afonso AM; Sogni P; Pol S; Mallet V
    Hepatology; 2018 Jun; 67(6):2468-2470. PubMed ID: 29194671
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired Gitelman Syndrome Secondary to Bendamustine Use.
    Rogers A; Gandhi P; Bautista J; Tang J
    R I Med J (2013); 2018 Nov; 101(9):36-38. PubMed ID: 30384518
    [No Abstract]   [Full Text] [Related]  

  • 5. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
    Musto P; Fraticelli VL; Mansueto G; Madonna E; Nozza A; Andriani A; Mussetti A; Ballanti S; Bongarzoni V; Baraldi A; Patriarca F; Vincelli D; Falcone A; Derudas D; Califano C; Zambello R; Mele G; Fragasso A; Baldini L; Storti S
    Leuk Lymphoma; 2015 May; 56(5):1510-3. PubMed ID: 25651428
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
    Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
    Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 8. Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis.
    Tefferi A; Cerquozzi S; Liaw J
    Am J Hematol; 2016 Feb; 91(2):E6-7. PubMed ID: 26587685
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
    Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
    Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
    [No Abstract]   [Full Text] [Related]  

  • 11. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
    Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
    D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
    Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
    [No Abstract]   [Full Text] [Related]  

  • 13. [II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
    Ogura M
    Gan To Kagaku Ryoho; 2012 May; 39(5):736-42. PubMed ID: 22701900
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
    Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
    Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
    Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
    Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Honda A; Taoka K; Maki H; Kurokawa M
    Ann Hematol; 2023 Jan; 102(1):243-244. PubMed ID: 36369496
    [No Abstract]   [Full Text] [Related]  

  • 19. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
    Elsoueidi R; Mulat A; Mourad H
    J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
    Gyan E; Sonet A; Brice P; Anglaret B; Laribi K; Fruchart C; Tilly H; Araujo C; Soubeyran P; Gonzalez H; Morineau N; Nicolas-Virelizier E; Ghesquières H; Salles B; Bouabdallah R; Orfeuvre H; Fahri J; Couturier O; Xerri L; Feugier P;
    Br J Haematol; 2018 Oct; 183(1):76-86. PubMed ID: 30117149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.